{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:12:10Z","timestamp":1792336330339,"version":"4.4.0"},"reference-count":193,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.critrevonc.2005.03.010","type":"journal-article","created":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T12:47:26Z","timestamp":1133268446000},"page":"379-396","source":"Crossref","is-referenced-by-count":84,"title":["Cancer of the prostate"],"prefix":"10.1016","volume":"56","author":[{"given":"Sergio","family":"Bracarda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"de Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Prayer-Galetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Valdagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2005.03.010_bib1","series-title":"Cancer incidence, mortality and prevalence worldwide, version 1.0","author":"Ferlay","year":"2001"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B","article-title":"International trends and patterns of prostate cancer incidence and mortality","volume":"85","author":"Hsing","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib3","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jnci\/91.12.1025","article-title":"Cancer surveillance series: interpreting trends in prostate cancer\u2013part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality","volume":"91","author":"Feuer","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/93.11.824","article-title":"Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends","volume":"93","author":"Howe","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1097-0142(19950101)75:1+<295::AID-CNCR2820751313>3.0.CO;2-U","article-title":"Male genital cancers","volume":"75","author":"Gilliland","year":"1995","journal-title":"Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2005.03.010_bib6","article-title":"Survival of cancer patients in Europe: the EUROCARE-3 study","volume":"14","author":"Berrino","year":"2003","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2005.03.010_bib7","doi-asserted-by":"crossref","first-page":"V61","DOI":"10.1093\/annonc\/mdg754","article-title":"EUROCARE-3: survival of cancer patients diagnosed 1990\u201394-results and commentary","volume":"14","author":"Sant","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(20000815)89:4<893::AID-CNCR24>3.0.CO;2-9","article-title":"Toward a comparison of survival in American and European cancer patients","volume":"89","author":"Gatta","year":"2000","journal-title":"Cancer"},{"issue":"Suppl. 12","key":"10.1016\/j.critrevonc.2005.03.010_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/028418699432996","article-title":"Survival of cancer patients in Finland 1955\u20131994","volume":"38","author":"Dickman","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib10","series-title":"Cancer survival trends in England and Wales, 1971\u20131995: deprivation and NHS region. Studies in medical and population subjects No. 61","author":"Coleman","year":"1999"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/annonc\/mdf127","article-title":"Cancer prevalence in European registry areas","volume":"13","author":"Micheli","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib12","unstructured":"Parkin DM, Muir CS, Whelan S, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. Lyon: International Agency for Research on cancer, vol. VII, IARC Scient. Publ. No. 120. book 1997."},{"key":"10.1016\/j.critrevonc.2005.03.010_bib13","unstructured":"WCRF & AICR. World Cancer Research Fund and American Institute for Cancer Research, Food, Nutrition and Prevention of Cancer: a Global Perspective. Washington: American Institute of Cancer Research, book 1997."},{"key":"10.1016\/j.critrevonc.2005.03.010_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/oxfordjournals.epirev.a000779","article-title":"Occupation and prostate cancer","volume":"23","author":"Parent","year":"2001","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0895-827","article-title":"Evidence of an X-linked or recessive genetic component to prostate cancer risk","volume":"1","author":"Monroe","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/oxfordjournals.aje.a117495","article-title":"Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada","volume":"141","author":"Whittemore","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jnci\/86.11.872","article-title":"Re: prostate cancer and the androgen receptor","volume":"86","author":"Coetzee","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/oxfordjournals.epirev.a000787","article-title":"Impact of screening on incidence and mortality of prostate cancer in the United States","volume":"23","author":"Potosky","year":"2001","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0046-8177(97)90097-6","article-title":"The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma","volume":"28","author":"Qian","year":"1997","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib20","series-title":"Robbins pathologic basis of disease","article-title":"The male genital tract","author":"Cotran","year":"1999"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1126\/science.274.5291.1371","article-title":"Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search","volume":"274","author":"Smith","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib22","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/jnci\/91.18.1574","article-title":"Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma","volume":"91","author":"Sato","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib23","first-page":"4291","article-title":"Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage","volume":"59","author":"McMenamin","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib24","series-title":"Prostae cancer: biology genetics and the new therapeutics","article-title":"Tumor suppressor genes in prostate cancer","author":"Bookstein","year":"2001"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib25","first-page":"1567","article-title":"Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers","volume":"148","author":"Krajewska","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1097-0142(19920701)70:1+<235::AID-CNCR2820701311>3.0.CO;2-G","article-title":"Pathology of carcinoma of the prostate","volume":"70","author":"Mostofi","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib27","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/1097-0142(19950115)75:2<530::AID-CNCR2820750216>3.0.CO;2-Y","article-title":"Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens","volume":"75","author":"Peller","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00000478-199304000-00003","article-title":"Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate","volume":"17","author":"Bastacky","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000474164","article-title":"Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma","volume":"30","author":"Bostwick","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0094-0143(05)70164-6","article-title":"Pathologic assessment of the surgical specimen","volume":"28","author":"Epstein","year":"2001","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-4295(89)90228-8","article-title":"Early detection and screening for prostatic cancer","volume":"34","author":"Chodak","year":"1989","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.300.6731.1041","article-title":"Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population","volume":"300","author":"Pedersen","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-5347(17)38491-4","article-title":"Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate","volume":"145","author":"Oesterling","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men","volume":"151","author":"Catalona","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib35","series-title":"Carcinoma of the prostate","article-title":"The role of prostate specific antigen in the management of prostate cancer","author":"Elgamal","year":"1996"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0022-5347(17)37401-3","article-title":"Screening for prostatic carcinoma with prostate specific antigen","volume":"147","author":"Brawer","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib37","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000474626","article-title":"The state of prostate cancer screening in the United States","volume":"23","author":"Haas","year":"1993","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0022-5347(01)65337-0","article-title":"Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens\u2014a different view","volume":"157","author":"Elgamal","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib40","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.267.16.2215","article-title":"Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease","volume":"267","author":"Carter","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib41","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q","article-title":"Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume","volume":"71","author":"Schmid","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib42","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jama.270.7.860","article-title":"Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges","volume":"270","author":"Oesterling","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib43","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0022-5347(01)66260-8","article-title":"Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis","volume":"155","author":"Partin","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib44","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","article-title":"Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer","volume":"147","author":"Benson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1464-410X.1995.tb07829.x","article-title":"Evaluation of patients with diseases of the prostate using prostate-specific antigen density","volume":"76","author":"Wolff","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib46","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0022-5347(01)64961-9","article-title":"Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction","volume":"157","author":"Zlotta","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib47","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jama.274.15.1214","article-title":"Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening","volume":"274","author":"Catalona","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib48","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0022-5347(17)37041-6","article-title":"Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men","volume":"148","author":"Gustafsson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.3.CO;2-M","article-title":"The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project","volume":"77","author":"Mettlin","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib50","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/S0022-5347(17)32460-6","article-title":"Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography","volume":"152","author":"Ellis","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib51","first-page":"343","article-title":"Prostate ultrasound in screening, diagnosis and staging of prostate cancer","volume":"4","author":"Jones","year":"1990","journal-title":"Probl Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib52","series-title":"Carcinoma of the prostate. Innovations in management","article-title":"Imaging modalities in diagnosis and staging of carcinoma of the prostate","author":"Oyen","year":"1996"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib53","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1464-410X.1994.tb09189.x","article-title":"The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation","volume":"74","author":"Patel","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib54","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.1464-410X.1996.01014.x","article-title":"Infection after transrectal core biopsies of the prostate\u2013risk factors and antibiotic prophylaxis","volume":"77","author":"Aus","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib55","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1464-410X.1993.tb15993.x","article-title":"Multiple transrectal ultrasound-guided prostatic biopsies\u2013true morbidity and patient acceptance","volume":"71","author":"Collins","year":"1993","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-5347(17)38664-0","article-title":"Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate","volume":"142","author":"Hodge","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib57","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3109\/00365599709030659","article-title":"Diagnosis of prostate cancer: optimal number of prostate biopsies related to serum prostate-specific antigen and findings on digital rectal examination","volume":"31","author":"Aus","year":"1997","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-4295(95)96168-2","article-title":"Making the most out of six systematic sextant biopsies","volume":"45","author":"Stamey","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib59","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0022-5347(17)35304-1","article-title":"Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values","volume":"151","author":"Keetch","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0090-4295(99)80451-8","article-title":"Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels","volume":"47","author":"Roehrborn","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00005392-199707000-00004","article-title":"The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues","volume":"158","author":"Haggman","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000474176","article-title":"Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia","volume":"30","author":"Zlotta","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib63","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jnci\/83.5.329","article-title":"Routine screening for cancer of the prostate","volume":"83","author":"Gerber","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib64","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0094-0143(21)01061-2","article-title":"The present status of radical prostatectomy for stages A and B prostatic cancer","volume":"2","author":"Jewett","year":"1975","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib65","unstructured":"UICC. UICC (International Union Against Cancer). TNM classification of malignant tumours. Sobin LH, Wittekind Ch, editors. 6th ed. New York Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss. book 2002."},{"key":"10.1016\/j.critrevonc.2005.03.010_bib66","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1464-410X.1978.tb02798.x","article-title":"The role of bone scanning in the assessment of prostatic carcinoma","volume":"50","author":"McGregor","year":"1978","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib67","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1464-410X.1978.tb02797.x","article-title":"Bone scanning and plasma phosphatases in carcinoma of the prostate","volume":"50","author":"O\u2019Donoghue","year":"1978","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib68","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.277.18.1445","article-title":"Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update","volume":"277","author":"Partin","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib69","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(17)35410-1","article-title":"The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer","volume":"150","author":"Partin","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib70","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.1999.17.5.1499","article-title":"Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer","volume":"17","author":"Kattan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000019922","article-title":"Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics","volume":"36","author":"Graefen","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib72","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0022-5347(05)67713-0","article-title":"Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens","volume":"163","author":"Stamey","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-5347(01)65967-6","article-title":"Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy","volume":"156","author":"Lerner","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib75","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jama.280.11.975","article-title":"Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer","volume":"280","author":"Albertsen","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib76","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.274.8.626","article-title":"Long-term survival among men with conservatively treated localized prostate cancer","volume":"274","author":"Albertsen","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib78","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000475067","article-title":"The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate","volume":"28","author":"Robinson","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib79","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/1097-0142(19921101)70:9<2302::AID-CNCR2820700915>3.0.CO;2-2","article-title":"Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer","volume":"70","author":"Matzkin","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0025-6196(12)61615-2","article-title":"Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy","volume":"69","author":"Ruckle","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib81","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199401273300403","article-title":"Results of conservative management of clinically localized prostate cancer","volume":"330","author":"Chodak","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib82","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00005392-199805000-00003","article-title":"An analysis of watchful waiting for clinically localized prostate cancer","volume":"159","author":"Steinberg","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib83","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa012794","article-title":"A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer","volume":"347","author":"Holmberg","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib84","series-title":"Proceedings of the First International Consultation on Prostatic Cancer","first-page":"227","article-title":"Treatment of localised disease: treatment of clinically localised prostete cancer T1\/T2","author":"Huland","year":"1997"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib85","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0022-5347(17)56718-X","article-title":"An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery","volume":"121","author":"Reiner","year":"1979","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib86","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-5347(17)53012-8","article-title":"Impotence following radical prostatectomy: insight into etiology and prevention","volume":"128","author":"Walsh","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib87","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-5347(17)43253-8","article-title":"Prostate shape, external striated urethral sphincter and radical prostatectomy: the apical dissection","volume":"138","author":"Myers","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/(SICI)1096-9098(199901)70:1<49::AID-JSO9>3.0.CO;2-X","article-title":"Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: a preliminary report","volume":"70","author":"Loughlin","year":"1999","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib89","first-page":"178","article-title":"Management of stage T1a prostate cancer","volume":"14","author":"Lowe","year":"1996","journal-title":"Semin Urol Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib90","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0022-5347(17)32370-4","article-title":"Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C)","volume":"152","author":"Epstein","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib91","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0094-0143(21)00921-6","article-title":"PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors","volume":"20","author":"Oesterling","year":"1993","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib92","first-page":"123","article-title":"Total prostatectomy for clinically localized prostate cancer: long-term surgical results and current morbidity","author":"Gibbons","year":"1988","journal-title":"NCI Monogr"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib93","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0094-0143(05)70386-4","article-title":"Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control","volume":"24","author":"Pound","year":"1997","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib94","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0022-5347(05)67890-1","article-title":"Laparoscopic radical prostatectomy: the Montsouris experience","volume":"163","author":"Guillonneau","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib95","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0090-4295(95)80017-4","article-title":"Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection","volume":"45","author":"Bishoff","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib96","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0022-5347(17)35239-4","article-title":"Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer","volume":"151","author":"Bluestein","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib97","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0090-4295(94)80050-2","article-title":"Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer","volume":"44","author":"Narayan","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib98","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0022-5347(01)66466-8","article-title":"Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results","volume":"155","author":"Parra","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib99","first-page":"398","article-title":"Early versus delayed endocrine treatment in pN1-3M0 prostate cancer without local treatment of the primary tumor. Results of EORTC 30846\u2014a phase III study","volume":"169","author":"Schroeder","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/01.ju.0000049032.38743.c7","article-title":"Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?","volume":"169","author":"Bader","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0090-4295(89)90103-9","article-title":"Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome","volume":"33","author":"Zincke","year":"1989","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib102","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0022-5347(01)63917-X","article-title":"Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation","volume":"159","author":"Seay","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib103","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/S0022-5347(05)65536-X","article-title":"Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer","volume":"166","author":"Zincke","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib104","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P","article-title":"Risk of prostate carcinoma death in patients with lymph node metastasis","volume":"91","author":"Cheng","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF00184109","article-title":"Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival?","volume":"12","author":"Frazier","year":"1994","journal-title":"World J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib106","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib107","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.ju.0000113202.37783.1f","article-title":"Lymph node positive prostate cancer: long-term survival data after radical prostatectomy","volume":"171","author":"Zwergel","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib108","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0022-5347(01)67067-8","article-title":"Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group","volume":"154","author":"Soloway","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib109","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0022-5347(05)68092-5","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure","volume":"162","author":"Meyer","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib110","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0022-5347(01)63230-0","article-title":"Hormonal treatment before radical prostatectomy: a 3-year followup","volume":"159","author":"Aus","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib111","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1159\/000020366","article-title":"4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European tudy Group on Neoadjuvant Treatment of Prostate Cancer","volume":"38","author":"Schulman","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib112","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0022-5347(05)67008-5","article-title":"Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?","volume":"164","author":"Scolieri","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib114","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/1097-0142(19910915)68:6<1265::AID-CNCR2820680615>3.0.CO;2-G","article-title":"The role of radical surgery in the management of radiation recurrent and large volume prostate cancer","volume":"68","author":"Moul","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib115","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0022-5347(17)35913-X","article-title":"Treatment of clinical local failure after radiation therapy for prostate carcinoma","volume":"150","author":"Schellhammer","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib116","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0360-3016(98)00089-3","article-title":"Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions","volume":"41","author":"Hanks","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib117","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2000.18.23.3904","article-title":"Preliminary results of a randomized radiotherapy dose-escalation study comparing 70Gy with 78Gy for prostate cancer","volume":"18","author":"Pollack","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib118","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-5347(05)65855-7","article-title":"High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer","volume":"166","author":"Zelefsky","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib119","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0167-8140(99)00100-0","article-title":"Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer","volume":"55","author":"Zelefsky","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/srao.2002.28667","article-title":"Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes","volume":"12","author":"Blasko","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib121","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0360-3016(03)00739-9","article-title":"Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience","volume":"57","author":"Sylvester","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib122","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0360-3016(01)02657-8","article-title":"Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study","volume":"52","author":"Locke","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib123","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0167-8140(00)00288-7","article-title":"The role of external beam radiotherapy with I-125\/Pd-103 brachytherapy for prostate carcinoma","volume":"57","author":"Blasko","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib124","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0360-3016(96)00214-3","article-title":"103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma","volume":"35","author":"Dattoli","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib125","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib126","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","article-title":"Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate","volume":"49","author":"Lawton","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib127","first-page":"327","article-title":"RTOG protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate","volume":"19","author":"Hanks","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib129","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0022-5347(01)66888-5","article-title":"Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity","volume":"154","author":"Lerner","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0090-4295(93)90159-8","article-title":"Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer","volume":"41","author":"Morgan","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib131","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000474189","article-title":"DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy","volume":"30","author":"Di Silverio","year":"1996","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib132","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000480794","article-title":"Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis","volume":"32","author":"Gerber","year":"1997","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib133","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s001200050109","article-title":"Radical prostatectomy as primary monotherapy in capsule penetrating prostatic carcinoma. 15 years outcome","volume":"36","author":"Theiss","year":"1997","journal-title":"Urologe A"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib134","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0022-5347(17)35037-1","article-title":"Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer","volume":"151","author":"van den Ouden","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib135","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0022-5347(01)62546-1","article-title":"Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy","volume":"160","author":"van den Ouden","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib136","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000020311","article-title":"Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer","volume":"38","author":"van Poppel","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib137","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0090-4295(02)01502-9","article-title":"Postprostatectomy radiotherapy for high-risk prostate cancer","volume":"59","author":"Mayer","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib138","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0090-4295(99)00219-8","article-title":"Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer","volume":"54","author":"Vicini","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib139","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0090-4295(99)00299-X","article-title":"Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns","volume":"54","author":"Nudell","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib140","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1053-4296(03)70006-X","article-title":"Radiation therapy after radical prostatectomy: a review of the issues and options","volume":"13","author":"Valicenti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib141","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1464-410X.2002.02698.x","article-title":"Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer","volume":"89","author":"Petrovich","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib142","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0360-3016(03)00069-5","article-title":"Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer","volume":"56","author":"Taylor","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib143","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0167-8140(01)00302-4","article-title":"Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate","volume":"59","author":"Catton","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib144","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-8140(01)00439-X","article-title":"Salvage radiotherapy for PSA failure after radical prostatectomy","volume":"61","author":"Parker","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib145","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists\u2019 Collaborative Group","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib146","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial","volume":"79","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib147","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T","article-title":"The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer","volume":"76","author":"Small","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib148","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0002-9343(99)80323-4","article-title":"Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer","volume":"98","author":"Figg","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib149","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0022-5347(01)64984-X","article-title":"Antiandrogen withdrawal syndrome with nilutamide","volume":"157","author":"Gomella","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib150","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/1097-0142(19930201)71:3+<1068::AID-CNCR2820711427>3.0.CO;2-5","article-title":"Ketoconazole and liarozole in the treatment of advanced prostatic cancer","volume":"71","author":"Mahler","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib151","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G","article-title":"Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer","volume":"71","author":"Yagoda","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib152","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.1999.17.10.3160","article-title":"Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial","volume":"17","author":"Hudes","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib153","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0090-4295(97)00228-8","article-title":"A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer","volume":"50","author":"Pienta","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib154","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib155","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.critrevonc.2005.03.010_bib156","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1023\/A:1013043031392","article-title":"Quality of life studies and genito-urinary tumors","volume":"12","author":"Berretto","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib157","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1200\/JCO.1997.15.9.3156","article-title":"Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer","volume":"15","author":"Hudes","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib158","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0090-4295(01)01011-1","article-title":"Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer","volume":"58","author":"Haas","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib159","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/1097-0142(20010601)91:11<2039::AID-CNCR1230>3.0.CO;2-R","article-title":"A phase I\/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma","volume":"91","author":"Ferrari","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib160","first-page":"34","article-title":"Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer","volume":"26","author":"Kreis","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib161","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1999.17.3.958","article-title":"Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer","volume":"17","author":"Petrylak","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib162","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2001.19.9.2509","article-title":"Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B","volume":"19","author":"Savarese","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib163","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib164","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib165","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/0277-5379(91)90254-B","article-title":"Palliation of bone metastases","volume":"27","author":"Hoskin","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib166","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0167-8140(92)90338-U","article-title":"A prospective randomised trial of 4Gy or 8Gy single doses in the treatment of metastatic bone pain","volume":"23","author":"Hoskin","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib167","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib168","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0167-8140(97)00112-6","article-title":"Spinal cord compression in prostate cancer: treatment outcome and prognostic factors","volume":"44","author":"Huddart","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib169","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/clon.2001.0054","article-title":"Spinal cord compression\u2013what are the treatment standards?","volume":"14","author":"Hardy","year":"2002","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1108\/09526869610124209","article-title":"Does the service at a large oncologic out-patient clinic satisfy the patients\u2019 perceived need?","volume":"9","author":"Fossa","year":"1996","journal-title":"Int J Health Care Qual Assur"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib171","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.273.2.129","article-title":"Quality-of-life outcomes in men treated for localized prostate cancer","volume":"273","author":"Litwin","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib172","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0090-4295(93)90524-E","article-title":"Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988\u20131990 (updated June 1993)","volume":"42","author":"Fowler","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib173","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0022-5347(17)32399-6","article-title":"Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer","volume":"152","author":"Zincke","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib174","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0022-5347(05)68578-3","article-title":"Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies","volume":"162","author":"Catalona","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0090-4295(99)00397-0","article-title":"Patient-reported urinary continence and sexual function after anatomic radical prostatectomy","volume":"55","author":"Walsh","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib176","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jama.283.3.354","article-title":"Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study","volume":"283","author":"Stanford","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib177","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0022-5347(01)65488-0","article-title":"Risk factors for urinary incontinence after radical prostatectomy","volume":"156","author":"Eastham","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib178","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/S0022-5347(01)63297-X","article-title":"Anatomy of radical prostatectomy as defined by magnetic resonance imaging","volume":"159","author":"Myers","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib179","first-page":"201","article-title":"The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer","volume":"111","author":"Scardino","year":"2000","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib180","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0022-5347(01)65334-5","article-title":"Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy","volume":"157","author":"Hammerer","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib181","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0022-5347(17)38512-9","article-title":"Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles","volume":"145","author":"Quinlan","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib182","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0022-5347(05)66921-2","article-title":"Factors predicting recovery of erections after radical prostatectomy","volume":"164","author":"Rabbani","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib183","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0302-2838(02)00219-1","article-title":"Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy","volume":"42","author":"Noldus","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib184","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-5347(01)67251-3","article-title":"Nerve sparing radical prostatectomy: a different view","volume":"154","author":"Geary","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib185","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0022-5347(05)67819-6","article-title":"Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy","volume":"163","author":"Kao","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib186","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0360-3016(95)00219-7","article-title":"Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients","volume":"33","author":"Sandler","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib187","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/S0022-5347(17)35915-3","article-title":"Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma","volume":"150","author":"Zelefsky","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib188","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0360-3016(93)90978-5","article-title":"Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma","volume":"26","author":"Benk","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib189","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.radonc.2003.08.003","article-title":"Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer","volume":"69","author":"Greco","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib190","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0360-3016(02)03245-5","article-title":"Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer","volume":"54","author":"Huang","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib191","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","article-title":"Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years","volume":"164","author":"Amling","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib192","first-page":"1035","article-title":"Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel","volume":"37","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2005.03.010_bib193","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1259\/0007-1285-65-778-861","article-title":"Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?","volume":"65","author":"Sissons","year":"1992","journal-title":"Br J Radiol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280500065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280500065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T14:34:15Z","timestamp":1626791655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084280500065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":193,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S104084280500065X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2005.03.010","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}